- Policy
- Dupixent targeting atopic dermatitis was launched
- by Lee, Tak-Sun Oct 8, 2020 06:25am
- Since the first biological drug Dupixent targeting atopic dermatitis was launched in Korea, other foreign-funded pharmaceutical companies are also developing new drugs. There are four clinical trials approved in Korea this year. On the 6th, the MFDS approved the phase III clinical trial protocol of Lebrikizumab. It is evaluated for effica
- Policy
- The bioequivalence test of Lixiana's generic has begun
- by Lee, Tak-Sun Oct 8, 2020 06:23am
- The development of a generic for Lixiana (Edoxaban, Daiichi Sankyo Korea), which was released as the latest among new oral anticoagulants (NOAC), has begun. Lixiana was approved six years later than the country's first NOAC drug, Xarelto (Rivaroxaban, Bayer Korea), but it is currently recording the highest sales performance in the market.
- Policy
- 17 new drugs including Verzenio got to expand coverage
- by Kim, Jung-Ju Oct 8, 2020 06:23am
- Apparently, total 13 new drugs have been listed for healthcare reimbursement this year. Total four already-listed drugs had their reimbursement expanded with the coverage enhancement policy. The record demonstrates the social consensus has flexibly expanded healthcare coverage even on expensive drug for a limited patient size. Daily Pharm su
- Policy
- Abbott accused of sponsoring academic society too often
- by Lee, Jeong-Hwan Oct 7, 2020 06:08am
- Global pharmaceutical and medical device company Abbott has been accused of providing questionable financial benefit to healthcare providers that exceeded the legal amount stipulated in the ‘Korean Sunshine Act.’ Apparently for a year, Abbott has sponsored Korean Society of Interventional Cardiology (KSIC) an approximate total of 250 mi
- Policy
- Mishandled flu vaccines' recognition was announced in 10 hr
- by Lee, Jeong-Hwan Oct 6, 2020 06:24am
- Criticism was raised that the KDCA announced the suspension of vaccination after about 10 hours of being aware of the flu vaccine exposure to room temperature, causing damage to the public. The KDCA announced to domestic medical institutions that Shinsung Pharm’s vaccines would be halted at 11 pm on the 21st of last month, and the recogni
- Policy
- Additional evidences asked for 3 patients using Spinraza
- by Lee, Hye-Kyung Oct 6, 2020 06:23am
- The South Korean health authority has asked three preliminary approval applicants seeking to use spinal muscular atropy (SMA) treatment Spinraza with coverage to submit supplementary evidences. After the initial approval on reimbursed use of Spinraza, the applicant has to hand in monitoring report every four months before administering t
- Policy
- Daewoong's DWP16001, approved for Phase III clinical trial
- by Lee, Tak-Sun Oct 5, 2020 06:22am
- The SGLT-2 diabetes treatment drug being developed by Daewoong is entering phase III of clinical trial. This drug is expected to become the first domestic SGLT-2 diabetes drug if it obtains product approval. On the 29th of last month, the MFDS approved phase III clinical trial plan for Daewoong's new drug candidate 'DWP16001'. DWP16001
- Policy
- Health vice-minister answers questions on MOHW drug pricing
- by Kim, Jung-Ju Oct 5, 2020 06:21am
- Kang Do-tae (Master’s degree in Public Administration at Seoul National University) has been appointed as a first second vice-minister of Ministry of Health and Welfare (MOHW) to lead the health sector of the ministry amid COVID-19. And during an interview on him, the vice-minister expressed his commitment to not only focus on the infectious di
- Policy
- Off-label coverage on Cellcept and Mabthera expanded
- by Kim, Jung-Ju Oct 5, 2020 06:21am
- From next month, the off-label reimbursement would be expanded on Roche Korea’ immunosuppressant Cellcept Capsule (mycophenolate mofetil) and chronic lymphocytic leukemia and rheumatoid arthritis treatment Mabthera injection (rituximab). Lilly Korea’s psoriatic arthritis and ankylsoing spondylitis treatment Taltz Prefilled Syringe Inj
- Policy
- A government-ruling party, pay attention to Syntekabio
- by Lee, Jeong-Hwan Oct 5, 2020 06:21am
- As it is known that the drug efficacy of the new drug substance for COVID-19 being developed by Syntekabio is more than twice that of Remdesivir, a government-ruling party is paying attention to this. On the 28th, Lee Nak-yeon, leader of the Democratic Party and Representative Han Jeoung-ae (General Manager of the National Disaster Recov
